A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
Merck Sharp & Dohme LLC
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed solid tumor by pathology report that is advanced/metastatic * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to study enrollment * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Participants with human immunodeficiency virus (HIV) infect…
Interventions
- DrugMK-0472
Oral Administration
- BiologicalPembrolizumab
IV infusion
- DrugMK-1084
Oral Administration
Locations (25)
- Northwestern Memorial Hospital ( Site 0002)Chicago, Illinois
- The University of Louisville, James Graham Brown Cancer Center ( Site 0004)Louisville, Kentucky
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0005)New Brunswick, New Jersey
- Princess Margaret Cancer Centre ( Site 0101)Toronto, Ontario
- Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)Montreal, Quebec